Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2803-2808

  Zeimet, Alain G ^a   Reimer, Daniel ^a   Radl, Alice C ^a   Reinthaller, Alexander ^b   Schauer, Christian ^c   Petru, Edgar ^d   Concin, Nicole ^a   Braun, Stephan ^a   Marth, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Intraperitoneal chemotherapy; Ovarian cancer; Platinum; Review; Taxane

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GOG 158; GOG 172; PACLITAXEL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPITHELIAL OVARIAN CANCER; EPITHELIUM TUMOR; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 69249195762     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. IARC: GLOBOCAN: Cancer incidence, mortality and prevalence worldwide http://www-dep.iarc.fr/, 2002.
2. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK and DuBeshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26): 1950-1955, 1996.
3. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S and Sickel J: Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwest Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 19(4): 1001-1007, 2001. (Pubitemid 32176274)
4. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA; Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1): 34-43, 2006. (Pubitemid 43048949)
5. Rao G, Crispens M and Rothenberg ML: Intraperitoneal chemotherapy for ovarian cancer: Overview and perspective. J Clin Oncol 25(20): 2867-2872, 2007. (Pubitemid 47123150)
6. Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A and Young RC: Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 103(1): 1-6, 2006.
7. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, François E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S and Brandely M: Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14(2): 343-350, 1996. (Pubitemid 26050993)
8. Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Tropé C, Wenzel L and Zeimet AG: Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 109(4): 645-649, 2007.
9. Jaaback K and Johnson N: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev J 25(1): CD005340, 2006.
10. Yen MS, Juang CM, Lai CR, Chao GC, Ng HT and Yuan CC: Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 72(1): 55-60, 2001.
11. du Bois A, Lück H, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Ulbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W and Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group: A randomized clinical trial of cisplatin/paclitaxel vs. carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17): 1320-1329, 2003.
12. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R; Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21(17): 3194-3200, 2003. (Pubitemid 46606249)
13. Isonishi S, Yasuda M, Takahashi F, Katsumata N, Kimura E, Aoki D, Jobo T, Terauchi F, Tsuda H and Sugiyama T: Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology Group. J Clin Oncol 26: 294s (abstr. 5506) 2008.
14. Wenzel LB, Huang HQ, Armstrong DK, Walker JL and Cella D; Gynecologic Oncology Group: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(4): 437-443, 2007.
15. Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK and Frick KD: Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol 106(3): 476-481, 2007.
16. Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK and Kulasingam S; Gynecologic Oncology Group: Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 26(25): 4144-4150, 2008.
17. Neijt JP, Engelsholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B and van Houwelingen HC: Exploratory phase III study of paclitaxel and cisplatin vs. paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18(17): 3084-3092, 2000. (Pubitemid 30677088)
18. Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida T, Sawai H, Aotani E and Kohno I: First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 90(3): 637-643, 2003.
19. Krasner CN, Seiden MV, Fuller AF Jr, Supko JG, Roche M, Kendall DL, Lee J, Berkowitz R, Berlin S and Matulonis UA: Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. Proc Am Soc Clin Oncol 25: (abstr 5521), 2007.
20. Fujiwara K, Suzuki S, Ishikawa H, Oda T, Aotani E and Kohno I: Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int J Gynecol Cancer 15(3): 426-431, 2005. (Pubitemid 40705536)
21. Krasner CN, Roche M, Horowitz NS, Supko JG, Lee SI and Oliva E: Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. N Engl J Med 354(15): 1615-1625, 2006.
22. Morgan RJ Jr, Synold TW, Xi B, Lim D, Shibata S, Margolin K, Schwarz RE, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Tetef M, Lin P, Paz B, Koczywas M, Wagman L, Chu D, Frankel P, Stalter S and Doroshow JH: Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 13(4): 1232-1237, 2007. (Pubitemid 46437052)
23. Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D and Spriggs D: Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial. Clin Cancer Res 10(9): 2962-2967; 2004: (Pubitemid 38619671)
24. Bos AM, De Vos FY, de Vries EG, Beijnen JH, Rosing H, Mourits MJ, van der Zee AG, Gietema JA and Willemse PH: A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. Eur J Cancer Mar 41(4): 539-548, 2005. (Pubitemid 40292733)
25. Gadducci A and Conte PF: Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. Int J Gynecol Cancer 18(5): 943-953, 2008.